As an industry leading Contract Development and Manufacturing Organization (CDMO) in the antibody-drug conjugate (ADC) space, we are offering a rapid approach for developing your ADC constructs. By using our extensive bioconjugation expertise, we can reduce your time to produce development-grade constructs for target molecule identification. We will leverage our established platform technology to efficiently turn antibody, linker, and payload into an ADC.

**Why choose ADC Express™?**

**Speed to selection:**
- Rapid production of multiple ADC constructs for screening in the discovery phase
- Our platform technology increases the efficiency of target molecule identification

**Speed to clinic:**
- Rely on our expertise to scale-up your target molecule
- Benefit from an established partner offering comprehensive services for GLP and GMP production
- Supply chain consolidation gives you comprehensive ADC services within one organization

**ADC Express™ Features**
- Mini-prep scale: 10–20 mg ADC construct
- Medium-prep scale: up to 100 mg ADC construct
- Certificate of testing with key quality attributes
  - ADC concentration
  - Payload density/DAR (drug-to-antibody ratio)
  - Monomer/aggregate content
  - Endotoxin

The Life Science business of Merck KGaA, Darmstadt, Germany operates as MilliporeSigma in the U.S. and Canada.
How does ADC Express™ work?

We offer a library of popular linker/payload options that can be combined with PEGs or ChetoSensar™ technology to rapidly produce multiple ADC constructs from a single mAb.

Comprehensive Solutions for Your ADC

We offer comprehensive supply chain reliability from discovery to commercialization of your ADC. This includes coordinated and collaborative services for the development, manufacturing, and testing of bulk drug substance and drug product. We offer a full range of services needed for ADCs:

- Biopharmaceutical process development services and clinical supplies for monoclonal antibodies
- Linker, payload, conjugation development, and manufacturing services
- Technology transfer, analytical method development, and validation
- Stability studies for bulk drug substance and drug product

ADC Conjugation and Manufacturing

With over 35 years of industry-leading experience in conjugation, we have the expertise needed to develop and deliver your bioconjugate or ADC. Our purpose-built manufacturing facilities are designed for the handling of HPAPIs, antibodies, linkers, and for performing complex bioconjugation processes.

- Safebridge® Cat. IV certified facility in St. Louis (MO), US with Grade C classified clean room environment
- Personnel and suites dedicated to ADC development, manufacturing, and testing
- Extensive analytical capabilities for characterization, including mass spectrometry, and cell-based assays
- Release testing and stability for both Bulk Drug Substance (BDS) and Drug Product (DP)
- Ability to manufacture batches up to 600 L/3 kg under Grade C classification either with multi-use or single-use equipment
- Segregated areas for potent solids handling, conjugation, and aseptic bulk filling
- Experience with >65 constructs, >600 development batches, >30 INDs, and >180 cGMP batches (>40 batches for commercial use)
- Random cysteine or lysine conjugation technology
- Site-directed conjugation via engineered mAbs or enzyme-catalyzed
- Alternate scaffolds & non-potent bioconjugates

Payloads and Linkers

Customers can choose from a library of linker/payloads to produce ADCs. Payloads will include, but not be limited to:

- Maytansines
- Auristatins
- Pyrrolobenzodiazepine (PBD) dimers
- Camptothecin (CPT)

With ADC Express™ we will screen and provide an assessment about best construct options.

For additional information please visit
SigmaAldrich.com/services/contract-manufacturing/adc-bioconjugation
To place an order or receive technical assistance, please visit
SigmaAldrich.com/services/contact-safc

© 2021 Merck KGaA, Darmstadt, Germany and/or its affiliates. All Rights Reserved. MilliporeSigma, the Vibrant M, SAFC, ChetoSensar and ADC Express are trademarks of Merck KGaA, Darmstadt, Germany or its affiliates. All other trademarks are the property of their respective owners. Detailed information on trademarks is available via publicly accessible resources.